Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2018 Nov 18:2018:4614802.
doi: 10.1155/2018/4614802. eCollection 2018.

Acute Onset of Exogenous Endophthalmitis after Dexamethasone Implant Injection Treated without Implant Removal

Affiliations
Case Reports

Acute Onset of Exogenous Endophthalmitis after Dexamethasone Implant Injection Treated without Implant Removal

George G Bastakis et al. Case Rep Ophthalmol Med. .

Abstract

We present a case of acute endophthalmitis after intravitreal dexamethasone implant injection and discuss the management of this rare and challenging case in which the implant could not be removed. A 50-year-old woman with a history of branch retinal vein occlusion in the right eye was treated with intravitreal dexamethasone implant injection for macular oedema. Four days after injection, the patient was admitted to the department with acute pain, decreased vision, and redness. A diagnosis of acute post-intravitreal injection endophthalmitis was made. A 23-guage (23G) vitrectomy was performed immediately to remove the implant, and a vitreous tap for culture and polymerase chain reaction was acquired during the procedure. We were unable to remove the dexamethasone implant during the vitrectomy because of dense membrane formation. At the end of the procedure, we injected intravitreal antibiotics (vancomycin and amikacin), and the patient was treated with fortified topical antibiotics and steroids. At the time of writing, 5 years later, the patient retains a best corrected visual acuity of 10/10 (6/6) with dexamethasone implant therapy maintenance. Intravitreal dexamethasone implant-associated endophthalmitis is a rare and challenging condition. Immediate 23G pars plana vitrectomy, even without removal of the implant, can lead to favourable visual results.

PubMed Disclaimer

Similar articles

Cited by

References

    1. Boyer D. S., et al. Three-year, randomized, sham-controlled trial of dexamethasone intravitreal implant in patients with diabetic macular edema. Ophthalmology. 2014;121(10):1904–1914. - PubMed
    1. Haller J. A., Bandello F., Belfort R., Jr., et al. Dexamethasone intravitreal implant in patients with macular edema related to branch or central retinal vein occlusion: twelve-month study results. Ophthalmology. 2011;118(12):2453–2460. doi: 10.1016/j.ophtha.2011.05.014. - DOI - PubMed
    1. Lowder C., Belfort R., Jr., Lightman S., et al. Dexamethasone intravitreal implant for noninfectious intermediate or posterior uveitis. JAMA Ophtalmology. 2011;129(5):545–553. doi: 10.1001/archophthalmol.2010.339. - DOI - PubMed
    1. Adeniran J. M. F., Jusufbegovic D., Schaal S. Common and rare ocular side-effects of the dexamethasone implant. Ocular Immunology and Inflammation. 2016:1–7. - PubMed
    1. Sigford D. K., Reddy S., Mollineaux C., Schaal S. Global reported endophthalmitis risk following intravitreal injections of anti-VEGF: a literature review and analysis. Clinical Ophthalmology. 2015;9:773–781. - PMC - PubMed

Publication types

LinkOut - more resources